Upload
waneta
View
41
Download
0
Tags:
Embed Size (px)
DESCRIPTION
Pharmacovigilance: challenges facing WHO . Shanthi Pal Leader, Medicines Safety Safety and Vigilance, WHO, Geneva. What is pharmacovigilance. - PowerPoint PPT Presentation
Citation preview
Pharmacovigilance: challenges facing WHO
Shanthi PalLeader, Medicines Safety
Safety and Vigilance,WHO, Geneva
What is pharmacovigilance
• The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problems.
(The Importance of Pharmacovigilance, WHO 2002)
• A tool for generating evidence to influence policies
WHO Global PV ProgrammeWhy??
• World Health Assembly Resolution 16.36
• INVITES Member States to arrange for a systematic collection of information on serious adverse drug reactions observed during the development of a drug and, in particular, after its release for general use.
Who?
WHO-HQGeneva
> 50 years
UMCWHO-CC Uppsala
> 40 years
NationalCentres
WHO-CCAccra(2009)
WHO-CCRabat(2010)
(2012)
WHO-CCOslo
>30 years
Policies,Norms, Guidance,Donor LiaisonResources
Technical supportCapacity buildingDatabase, tools , Signals
Capacity : Africa focusedPublic health focused
Capacity : Francophone & Arabic countries
ATC DDD
PV in academiaPatient reporting
ImplementCollect ADRsShare with WHO database
Challenges to PV in low and middle income countries (LMIC)
• Lack of political support• Lack of resources• Lack of competence• Lack of PV systems and/ or inadequate function• Lack of communication and
information exchange
% Implemented out of the
total countries in the region
% Implemented (of those with data available)
Number of Countries
with Indicator Implemented
Number of Countries with data available
Number of
Countries
Group of countries
94 94 45 48 48 A. Industrialized
13 38 5 13 39 B. Upper middle income
9 29 5 17 57 C1.Lower middle income
4 12 2 17 49 C2.Low income
Capacity to detect significant vaccine safety issue
WHO survey of PV systems in 55 countries
North America
Europe
Why is this a problem?
• More than 300 products in the pipeline for neglected diseases, HIV AIDS, TB and malaria
• At least half of them will be launched in the coming years in those very settings where there is little or no capacity for post approval monitoring
Developer Analysis, BVGH, 2012
Lead Optimization Preclinical Development
GLP Tox. Phase I Phase II Phase III
Delamanid (OPC-67683)GatifloxacinMoxifloxacinRifapentine
AZD5847Bedaquiline (TMC-207)LinezolidNovel Regimens2
PA-824RifapentineSQ-109Sutezolid (PNU-100480)
CPZEN-45DC-159aQ201SQ609SQ641
Preclinical DevelopmentDiscovery1 Clinical Development
DiarylquinolineDprE InhibitorsGyrB inhibitorsInhA InhibitorsLeuRS InhibitorsMGyrX1 inhibitorsMycobacterial Gyrase InhibitorsPyrazinamide AnalogsRiminophenazinesRuthenium (II) complexesSpectinamidesTranslocase-1 Inhibitors
Global TB Drug Pipeline
Updated: June 18, 2012
BTZ043TBA-354
www.newtbdrugs.org
4 Repurposed Drugs6 New Drugs
3 New Classes
Drugs currently in the regulatory review process
http://www.who.int/medicines/areas/quality_safety/safety_efficacy/saf_pub/en/
What can we do about it?
Build PV systems
Innovative solutions to support those systems
Network of WHO Collaborating Centres (CC) to support PV systems in countries
• Uppsala Monitoring Centre, Sweden
• WHO CC Accra, Ghana• WHO CC Rabat, Morocco• WHO CC Oslo, Norway• WHO CC Netherlands (Lareb) PV consultants in Africa, for Africa
Dedicated resources
Overcome technical barriers to PV in LMIC
• for receiving and storing ADR reports.
• The entered reports can be extracted as XML files
• can be transferred to other (E2b)databases
• A search and statistics module is built into the system
• Easy to use and error-checking ensures accuracy. Vigiflow
Task shifting: patients as partners
• Conventional models can't work in some settings
• All hands on board– Task shifting
• Patient reporting (more data, timely data, additional information)
Forward looking strategies through broad networks
Expanding and implementing the full scope of PV
Links with SSFFC networksLinks with medication errors networks
Pharmacovigilance investments will yield multiple benefits
• As an insurance for investments in public health interventions: – A comprehensive disease control approach must include quality
and safety as a component.• By Investing in PV, countries will have data on medicines
– To assist decision making by regulators, improve treatment strategies, health care practices, and treatment outcomes
• Pharmacovigilance data can guide procurement of effective medicines and reduce wastage
• Robust safety monitoring also provides a quality assurance mechanism and helps monitor programmatic implementation.